Epclusa 400/100mg Tablet

Epclusa 400/100mg Tablet is a combination medication containing two active ingredients: Sofosbuvir & Velpatasvir. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, while Velpatasvir is a pangenotypic NS5A inhibitor. This combination tablet is used in the treatment of chronic hepatitis C virus (HCV) infection in adults. Epclusa is effective against all six major genotypes of HCV and is often prescribed as a first-line treatment option.

Uses:

1. Chronic Hepatitis C Virus (HCV) Infection: Epclusa 400/100mg Tablet is indicated for the treatment of chronic HCV infection in adults. It is effective against all genotypes of HCV and is suitable for patients with or without cirrhosis. Epclusa works by inhibiting the replication of the hepatitis C virus, thereby reducing viral load and improving liver function.

Side Effects:

While Epclusa 400/100mg Tablet is generally well-tolerated, it may cause side effects in some individuals. Common side effects associated with Sofosbuvir and Velpatasvir include:

• Fatigue: Fatigue is a common side effect reported by patients undergoing treatment with Epclusa. Getting adequate rest and maintaining a healthy lifestyle can help manage fatigue.
• Headache: Headaches are frequently reported during treatment with Epclusa. Over-the-counter pain relievers may help alleviate headache symptoms.
• Nausea: Some patients may experience nausea while taking Epclusa. Eating small, frequent meals and avoiding spicy or greasy foods may help reduce nausea.
• Insomnia: Difficulty sleeping or insomnia may occur in some individuals. Establishing a regular sleep schedule and practicing relaxation techniques may improve sleep quality.

Precautions:

• Pregnancy and Breastfeeding: Epclusa 400/100mg Tablet should not be used during pregnancy due to the risk of fetal harm. Women of childbearing potential should use effective contraception during treatment and for a period after discontinuation of therapy. The safety of Epclusa during breastfeeding is unknown.
• Liver Dysfunction: Patients with severe liver impairment should use Epclusa with caution, as dosage adjustments may be necessary. Close monitoring of liver function is recommended during treatment.
• Drug Interactions: Epclusa may interact with certain medications, including other antiviral agents and drugs that affect liver enzymes. Patients should inform their healthcare provider about all medications they are taking before starting Epclusa treatment.
• HIV Coinfection: Epclusa is safe and effective for patients coinfected with HCV and HIV. However, close monitoring is necessary, especially for potential drug interactions and changes in HIV treatment.